AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

Clinical trial NCT07285694 · RECRUITING

Trial details

NCT number: NCT07285694
Sponsor: Arsenal Biosciences, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Start date: 2026-01-09
Primary completion: 2029-05-01
Enrollment: 190

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.